The Neuphoria Therapeutics Inc. (NEUP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Neuphoria uses its Forms 10-K, 10-Q and 8-K, along with proxy materials and other statements, to report on its business, pipeline, governance and material events.
For NEUP, current reports on Form 8-K are especially informative. Recent 8-K filings have described outcomes from the AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder, the decision to discontinue further development of the SAD program, and the company’s plans for a full strategic review of its operations and portfolio. Other 8-Ks detail the adoption of a limited-duration stockholder rights plan, notices from The Nasdaq Stock Market LLC regarding listing rule compliance, and the holding of the company’s annual meeting of stockholders.
Neuphoria’s filings also include information on strategic and governance matters. A definitive proxy statement on Schedule 14A outlines proposals for director elections, auditor ratification, and advisory votes on executive compensation and its frequency. Additional 8-K disclosures describe changes in executive roles and the entry into a consulting agreement with the company’s former full-time CEO to serve as interim CEO during the strategic review and potential strategic transaction process.
Investors can use NEUP’s periodic reports, when available, to review financial statements, license revenue, research and development spending, and cash position, as well as risk factor discussions related to its CNS drug development programs and collaborations with partners such as Merck & Co., Inc. These documents also provide context on Neuphoria’s single operating segment focused on allosteric ion channel modulators.
On Stock Titan, NEUP filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the key points in lengthy filings, highlight important clinical and strategic disclosures, and make it easier to locate information on topics such as trial outcomes, rights plans, annual meeting results, and material agreements. This allows users to quickly understand what each filing means for Neuphoria’s business and capital markets profile without reading every page in full.
Neuphoria Therapeutics Inc. director David Ian Wilson received a grant of 8,537 restricted stock units (RSUs) on January 20, 2026. Each RSU represents a contingent right to receive one share of Neuphoria common stock. Following this award, Wilson beneficially owns 15,412 derivative securities in the form of RSUs, held directly.
The grant was made under the company’s Board of Directors annual remuneration policy. The RSUs will fully vest if Wilson continues to serve the company through the earlier of the day before Neuphoria’s next annual shareholder meeting, which is expected to be no later than December 15, 2026, or the effective date of a change in control of the company.
Neuphoria Therapeutics director Peter Miles Winston Davies reported receiving 8,537 restricted stock units (RSUs) of the company on January 20, 2026. Each RSU represents a contingent right to receive one share of Neuphoria’s common stock.
The RSU grant was made under the Board of Directors’ annual remuneration policy, effectively functioning as stock-based compensation for his board service. Following this award, Davies beneficially owns 15,320 derivative securities, held directly.
The RSUs will fully vest only if he continues serving the company through the earlier of two events: the day before Neuphoria’s next annual shareholder meeting, which is expected to be no later than December 15, 2026, or the effective date of a change in control of the company.
Neuphoria Therapeutics Inc. director Alan Fisher reported a new equity award in the form of restricted stock units (RSUs). On 01/20/2026, he received 17,073 RSUs, each representing the right to receive one share of common stock at no purchase price. After this grant, he beneficially owns 30,731 derivative securities related to the company.
The RSUs were granted under the board of directors’ annual remuneration policy. They will fully vest if Fisher continues to serve the company through the earlier of the day before the next annual shareholder meeting, which is expected to be no later than December 15, 2026, or the effective date of a change in control of the company.
Neuphoria Therapeutics Inc. reported that director Jane Ryan received a grant of restricted stock units on January 20, 2026. The award covers 8,537 restricted stock units (RSUs), each representing a contingent right to receive one share of Neuphoria common stock, with a grant price of $0 per unit as part of the board’s annual remuneration policy. Following this grant, Ryan directly holds 15,550 derivative securities related to the company’s stock.
The RSUs will fully vest if Ryan continues serving the company through the earlier of the day before Neuphoria’s next annual shareholder meeting, which is expected to be no later than December 15, 2026, or the effective date of a change in control of the company.
Neuphoria Therapeutics Inc. reported that Spyridon “Spyros” Papapetropoulos, M.D. ceased serving as full-time President and CEO effective December 31, 2025, at which time his Employment Agreement terminated, though he will continue as a member of the board. Under that agreement, he is entitled to severance equal to his annual base salary, target bonus and medical insurance premiums, with 50% paid in 2025 and the remainder in installments during 2026, subject to normal payroll and withholding. His participation in company benefit plans ends, but his existing stock options will continue to vest and be exercisable under the equity plan.
Effective January 1, 2026, he entered into a Consulting Agreement under which he will serve as interim CEO for up to twelve months to support a contemplated strategic transaction and manage the leadership transition. He will receive consulting fees of $800 per hour for services up to approximately 40 hours per month, with total consulting hours limited to no more than twenty percent of the hours he worked as full-time CEO. The consulting arrangement ends automatically on the earlier of twelve months from entry or the closing of a strategic merger, change of control or similar transaction.
Neuphoria Therapeutics Inc. disclosed that it has regained compliance with Nasdaq Listing Rule 5620(a), which requires a qualified annual meeting of stockholders within twelve months of the fiscal year end. The company had previously received a deficiency notice on July 18, 2025 after not holding an annual meeting within twelve months of its June 30, 2024 fiscal year end. Neuphoria held its 2025 annual general shareholder meeting on December 12, 2025, and on December 18, 2025 Nasdaq staff notified the company that it is again in compliance and that the matter is closed.
Neuphoria Therapeutics Inc. held its Annual Meeting of Shareholders on December 12, 2025. Of the 2,357,613 shares of common stock outstanding and entitled to vote, 937,447 shares, or 39.76%, were represented in person or by proxy.
Shareholders voted on four proposals. For the election of Class I director nominees, votes included 759,850 shares for Peter Miles Davies and 758,571 for David Wilson, compared with 152,879 and 154,164 shares withheld, respectively. Stephen Doberstein received 136,780 votes for and 775,959 withheld, while Kimberly Smith received 136,740 for and 775,997 withheld.
Shareholders cast 807,022 votes for and 96,245 against ratifying Wolf & Company P.C. as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 34,180 abstentions. The advisory vote on executive compensation received 726,184 votes for and 154,109 against, with 32,445 abstentions. In the non-binding vote on the frequency of future say-on-pay votes, 184,974 votes favored one year, 27,153 two years, 585,857 three years, and 109,526 abstained.
Lynx1 Master Fund LP, a long-term biotech investor, has filed proxy materials seeking to elect two independent director nominees, Stephen Doberstein and Kimberly Smith, to the board of Neuphoria Therapeutics Inc. at the 2025 annual meeting using the BLUE proxy card. Lynx1’s investor presentation states that Neuphoria’s AFFIRM-1 Phase 3 trial for social anxiety disorder failed its primary and secondary endpoints and that the company plans to discontinue this program while exploring strategic alternatives.
Lynx1 claims Neuphoria rapidly raised cash through its at-the-market program after the trial failure, with total share count increasing by 128% over four weeks, which Lynx1 characterizes as highly dilutive. Lynx1 also highlights its non-binding all-cash indication of interest at $5.20 per share, described as a 27% premium to the then‑current price, and says subsequent dilution makes it difficult to price any revised bid. The fund argues that adding its nominees would strengthen board oversight of capital allocation and the strategic review.
Lynx1 Master Fund LP is leading a proxy contest at Neuphoria Therapeutics Inc. (NEUP) and has issued a proxy statement supplement urging stockholders to use its BLUE universal proxy card. Lynx1 asks investors to vote “FOR” its two board nominees, Stephen Doberstein and Kimberly Smith, and to withhold support from the company’s nominees.
The 2025 annual stockholder meeting will be held virtually on December 12, 2025, at 10:00 a.m. Eastern Time via www.cesonlineservices.com/neup25_vm, with online check-in starting at 9:45 a.m. Eastern Time. According to the company’s materials, telephone and Internet votes must be cast by 11:59 p.m. Eastern Time on December 11, 2025, and stockholders must preregister online by 10:00 a.m. Eastern Time on December 11, 2025 to attend.
The supplement explains that any previously submitted white proxy from company management can be revoked by submitting a later-dated BLUE proxy. Lynx1’s default voting instructions support its nominees, support Proposal 2, vote against Proposal 3, and select “1 year” on the advisory vote on the frequency of future executive compensation votes.
Neuphoria Therapeutics Inc. filed Amendment No. 7 to its prospectus supplement, updating its at‑the‑market program to offer and sell up to $20,000,000 of common stock from time to time through H.C. Wainwright & Co. as sales agent, under Rule 415(a)(4).
The company notes its public float exceeded $75.0 million beginning on November 3, 2025, so it is no longer limited by Form S‑3 “baby shelf” constraints; this amendment increases and fixes the continuous offering size at $20,000,000 as of the amendment date. Wainwright will use commercially reasonable efforts with no minimum sales requirement and will receive a 3.0% commission on the gross sales price per share. NEUP is listed on Nasdaq; the last reported sale price was $4.75 on November 13, 2025.